The pneumococcus: Carriage, disease and conjugate vaccines

Steven Obaro, Richard Adegbola

Research output: Contribution to journalReview article

138 Citations (Scopus)

Abstract

Modern biotechnology has made possible the rapid development and introduction into clinical care of a wide spectrum of potent antimicrobial agents. However, the battle against Streptococcus pneumoniae (pneumococcus) has remained fierce, as acquisition of resistance is even more rapid and these antimicrobial agents are rendered ineffective. Obtaining appropriate antibiotic treatment for severe invasive pneumococcal infections is now a major challenge in many regions of the world. The ground-breaking success of Haemophilus influenzae type b (Hib) conjugate vaccine has brought hope for the conquest of other capsulate bacteria. Recent results of efficacy trials of a heptavalent pneumococcal conjugate vaccine bring hope that protein conjugate vaccines will have a similar impact on pneumococcal disease. These multivalent vaccine formulations include pneumococcal serotypes that most often acquire antibiotic resistance and there is hope that the widespread application of these vaccines will decrease the incidence of multidrug-resistant infections. The potential reduction of pneumococcal disease could even extend to unimmunised younger siblings and the elderly residing with immunised young children, through its herd effect. However, in view of the multiplicity of serotypes and the biology of the pneumococcus, optimism must be tempered by caution.

Original languageEnglish (US)
Pages (from-to)98-104
Number of pages7
JournalJournal of Medical Microbiology
Volume51
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Conjugate Vaccines
Hope
Streptococcus pneumoniae
Anti-Infective Agents
Vaccines
Pneumococcal Infections
Haemophilus influenzae type b
Biotechnology
Microbial Drug Resistance
Siblings
Anti-Bacterial Agents
Bacteria
Incidence
Infection
Proteins
Serogroup
Therapeutics

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

The pneumococcus : Carriage, disease and conjugate vaccines. / Obaro, Steven; Adegbola, Richard.

In: Journal of Medical Microbiology, Vol. 51, No. 2, 01.01.2002, p. 98-104.

Research output: Contribution to journalReview article

@article{c05082025ec044c4a1b67c88879c34fe,
title = "The pneumococcus: Carriage, disease and conjugate vaccines",
abstract = "Modern biotechnology has made possible the rapid development and introduction into clinical care of a wide spectrum of potent antimicrobial agents. However, the battle against Streptococcus pneumoniae (pneumococcus) has remained fierce, as acquisition of resistance is even more rapid and these antimicrobial agents are rendered ineffective. Obtaining appropriate antibiotic treatment for severe invasive pneumococcal infections is now a major challenge in many regions of the world. The ground-breaking success of Haemophilus influenzae type b (Hib) conjugate vaccine has brought hope for the conquest of other capsulate bacteria. Recent results of efficacy trials of a heptavalent pneumococcal conjugate vaccine bring hope that protein conjugate vaccines will have a similar impact on pneumococcal disease. These multivalent vaccine formulations include pneumococcal serotypes that most often acquire antibiotic resistance and there is hope that the widespread application of these vaccines will decrease the incidence of multidrug-resistant infections. The potential reduction of pneumococcal disease could even extend to unimmunised younger siblings and the elderly residing with immunised young children, through its herd effect. However, in view of the multiplicity of serotypes and the biology of the pneumococcus, optimism must be tempered by caution.",
author = "Steven Obaro and Richard Adegbola",
year = "2002",
month = "1",
day = "1",
doi = "10.1099/0022-1317-51-2-98",
language = "English (US)",
volume = "51",
pages = "98--104",
journal = "Journal of Medical Microbiology",
issn = "0022-2615",
publisher = "Society for General Microbiology",
number = "2",

}

TY - JOUR

T1 - The pneumococcus

T2 - Carriage, disease and conjugate vaccines

AU - Obaro, Steven

AU - Adegbola, Richard

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Modern biotechnology has made possible the rapid development and introduction into clinical care of a wide spectrum of potent antimicrobial agents. However, the battle against Streptococcus pneumoniae (pneumococcus) has remained fierce, as acquisition of resistance is even more rapid and these antimicrobial agents are rendered ineffective. Obtaining appropriate antibiotic treatment for severe invasive pneumococcal infections is now a major challenge in many regions of the world. The ground-breaking success of Haemophilus influenzae type b (Hib) conjugate vaccine has brought hope for the conquest of other capsulate bacteria. Recent results of efficacy trials of a heptavalent pneumococcal conjugate vaccine bring hope that protein conjugate vaccines will have a similar impact on pneumococcal disease. These multivalent vaccine formulations include pneumococcal serotypes that most often acquire antibiotic resistance and there is hope that the widespread application of these vaccines will decrease the incidence of multidrug-resistant infections. The potential reduction of pneumococcal disease could even extend to unimmunised younger siblings and the elderly residing with immunised young children, through its herd effect. However, in view of the multiplicity of serotypes and the biology of the pneumococcus, optimism must be tempered by caution.

AB - Modern biotechnology has made possible the rapid development and introduction into clinical care of a wide spectrum of potent antimicrobial agents. However, the battle against Streptococcus pneumoniae (pneumococcus) has remained fierce, as acquisition of resistance is even more rapid and these antimicrobial agents are rendered ineffective. Obtaining appropriate antibiotic treatment for severe invasive pneumococcal infections is now a major challenge in many regions of the world. The ground-breaking success of Haemophilus influenzae type b (Hib) conjugate vaccine has brought hope for the conquest of other capsulate bacteria. Recent results of efficacy trials of a heptavalent pneumococcal conjugate vaccine bring hope that protein conjugate vaccines will have a similar impact on pneumococcal disease. These multivalent vaccine formulations include pneumococcal serotypes that most often acquire antibiotic resistance and there is hope that the widespread application of these vaccines will decrease the incidence of multidrug-resistant infections. The potential reduction of pneumococcal disease could even extend to unimmunised younger siblings and the elderly residing with immunised young children, through its herd effect. However, in view of the multiplicity of serotypes and the biology of the pneumococcus, optimism must be tempered by caution.

UR - http://www.scopus.com/inward/record.url?scp=0036171847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036171847&partnerID=8YFLogxK

U2 - 10.1099/0022-1317-51-2-98

DO - 10.1099/0022-1317-51-2-98

M3 - Review article

C2 - 11863272

AN - SCOPUS:0036171847

VL - 51

SP - 98

EP - 104

JO - Journal of Medical Microbiology

JF - Journal of Medical Microbiology

SN - 0022-2615

IS - 2

ER -